Insider Trading March 19, 2026

CoreWeave CFO Disposes $3.2M in Class A Shares as Stock Remains Volatile

Nitin Agrawal sold 38,456 CoreWeave Class A shares under a pre-set 10b5-1 plan; company continues product and data-center expansions amid mixed analyst views

By Nina Shah CRWV
CoreWeave CFO Disposes $3.2M in Class A Shares as Stock Remains Volatile
CRWV

CoreWeave Chief Financial Officer Nitin Agrawal sold 38,456 shares of Class A common stock on March 17, 2026, generating proceeds of $3,200,879. The trades were executed under a Rule 10b5-1 plan adopted May 22, 2025. The sale leaves Agrawal with a mix of direct and indirect holdings while the company reports several strategic partnerships, platform upgrades and a major data-center project even as analysts diverge on the stock's outlook.

Key Points

  • CFO Nitin Agrawal sold 38,456 CoreWeave Class A shares for $3,200,879 on March 17, 2026 under a Rule 10b5-1 plan adopted May 22, 2025 - impacts corporate insider activity monitoring.
  • Post-sale, Agrawal directly owns 189,892 Class A shares and has additional indirect holdings via spouse and two 2025 GRATs - relevant to insider ownership and voting dynamics.
  • CoreWeave continues to expand its AI infrastructure: a partnership to integrate W&B Inference with Cline, addition of Nvidia HGX B300 chips to its cloud platform, and a planned 300 MW AI data center in Regina, Saskatchewan - affecting AI infrastructure, cloud services and data-center markets.

Transaction overview

CoreWeave, Inc. (NASDAQ: CRWV) Chief Financial Officer Nitin Agrawal disposed of Class A common stock totaling $3,200,879 on March 17, 2026. The sale comprised 38,456 shares at transaction prices between $82.0527 and $84.7867, according to a Form 4 filing with the Securities and Exchange Commission.

The filing indicates the trades were executed pursuant to a pre-established Rule 10b5-1 trading plan that Agrawal adopted on May 22, 2025. The sales were reported in four tranches: 8,666 shares at a weighted average price of $82.0527; 16,090 shares at a weighted average price of $83.2159; 13,400 shares at a weighted average price of $83.9874; and 300 shares at a weighted average price of $84.7867.


Holdings after the sale

Following these transactions, Agrawal directly holds 189,892 shares of CoreWeave Class A common stock. The SEC filing also discloses indirect holdings: 34,905 shares held by a spouse, 81,000 shares held by the Yellowstone 2025 GRAT and 57,952 shares held by the Yosemite 2025 GRAT.


Share-price context and valuation note

CoreWeave's shares have shown notable short- and medium-term swings. The stock has declined 34% over the past six months while recording a 107% gain over the prior year. An InvestingPro analysis cited in the filing indicates the shares currently appear overvalued relative to the analyst platform's Fair Value estimate and points readers toward additional analysis and InvestingPro tips for deeper valuation context.


Recent company developments

Separately from the insider transaction, CoreWeave has announced several operational moves and partnerships that the company says expand its technical capabilities and infrastructure footprint.

  • CoreWeave said it entered a strategic partnership with Cline to integrate CoreWeave's W&B Inference into Cline's coding platform, enabling access to advanced AI models cited by the company, including NVIDIA Nemotron 3 Super.
  • The company has upgraded its cloud offering by adding Nvidia HGX B300 chips, which CoreWeave says increase memory capacity and bandwidth for its users.
  • In collaboration with Cerebras Systems Inc. and BCE Inc., CoreWeave is planning a 300-megawatt AI data center in Regina, Saskatchewan, with operations expected to begin in the first half of next year.

Analyst coverage

Analyst reactions to CoreWeave's positioning have been mixed. Oppenheimer initiated coverage with an Outperform rating, highlighting the company's specialized GPU infrastructure. In contrast, Bernstein initiated coverage with an Underperform rating, assigning a price target of $56 and expressing reservations about future market dynamics.


What the filing and recent moves show

The Form 4 provides a clear audit trail for a planned insider sale and the post-transaction ownership profile of a senior finance executive. At the same time, CoreWeave's product integrations, hardware upgrades and major data-center project underscore active efforts to expand capacity and service offerings. The stock's recent volatility and the differing analyst stances are noted in contemporaneous market commentary.

Risks

  • Stock price volatility - the shares have fallen 34% over six months even after a 107% gain over the past year, which may introduce market risk for shareholders and affect liquidity in the short term.
  • Valuation concerns - InvestingPro analysis flags the stock as appearing overvalued relative to its Fair Value, presenting valuation risk for investors considering new positions.
  • Divergent analyst views - opposing coverage from Oppenheimer (Outperform) and Bernstein (Underperform with a $56 price target) reflects uncertainty about near-term market dynamics and business trajectory.

More from Insider Trading

Revolution Medicines R&D Chief Sells $427,964 in Shares; Company Posts Q4 Loss Above Estimates Mar 19, 2026 Revolution Medicines CEO Sells $1.28 Million in Shares Under Pre‑Arranged Plan Mar 19, 2026 Revolution Medicines COO Disposes $455,918 in Stock as Shares Trade Near Yearly Peak Mar 19, 2026 Pale Fire Capital-led group buys $18.3M of Phreesia stock, raises stake to 7.65M shares Mar 19, 2026 Revolution Medicines General Counsel Disposes of Nearly $292,000 in RVMD Shares Mar 19, 2026